Skip to main content
. 2012 Jul 27;17(8):1014–1026. doi: 10.1634/theoncologist.2012-0043

Table 5.

Emerging tyrosine kinase inhibitors in metastatic breast cancer

graphic file with name onc00812-1129-t05.jpg

aMotesanib arm vs. bevacizumab arm and motesanib arm vs. placebo arm.

bApproved for use in advanced renal cell carcinoma.

Abbreviations: FGFR, fibroblast growth factor receptor; mPFS, median progression-free survival; mTTP, median time to progression; NS, nonsignificant; ORR, overall/objective response rate; PR; partial response; SD, stable disease.